Gilles Gosselin

Gilles Gosselin

Auto-generated profile, based on publicly available information

Gilles Gosselin

UMR 5247 CNRS-Université Montpellier-ENSCM, case courrier 1705, Place Eugène Bataillon, 34095 Montpellier Cedex 5, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
FAFrançois-René Alexandre
François-René Alexandre
EBEric Badaroux
Eric Badaroux
JBJohn P. Bilello
John P. Bilello
SBStéphanie Bot
Stéphanie Bot
TBTony Bouisset
Tony Bouisset
CDCyril B. Dousson
Cyril B. Dousson

1 February 1997 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IFIvan I. Fedorov
Ivan I. Fedorov
EKEma M. Kazmina
Ema M. Kazmina
GGGalina V. Gurskaya
Galina V. Gurskaya
MJMaxim V. Jasko
Maxim V. Jasko
VZValery E. Zavodnic
Valery E. Zavodnic
GGGilles Gosselin
Gilles Gosselin

1 September 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
GSGwenaëlle Sizun
Gwenaëlle Sizun
CPClaire Pierra
Claire Pierra
JPJérôme Peyronnet
Jérôme Peyronnet
EBEric Badaroux
Eric Badaroux
CRCéline Rabeson
Céline Rabeson
GGGilles Gosselin
Gilles Gosselin
Background: Ribonucleoside analogs possessing a β-methyl substituent at the 2′-position of the d-ribose moiety have been previously discovered to be potent and selective inhibitors of hepatitis C virus (HCV) replication, their triphosphates acting as alternative substrate inhibitors of the HCV RdRp NS5B. Results/methodology: In this article, the authors detail the synthesis, anti-HCV evaluation in cell-based replicon assays and structure–activity relationships of several phosphoramidate diester derivatives of 2′-C-methylguanosine (2′-MeG). Conclusion: The most promising compound, namely the O-[S-(hydroxyl)pivaloyl-2-thioethyl]{abbreviated as O-[(HO)tBuSATE)]} N-benzylamine phosphoramidate diester derivative (IDX184), was selected for further in vivo studies, and was the first clinical pronucleotide evaluated for the treatment of chronic hepatitis C up to Phase II trials.

1 May 1995 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
CPC. Périgaud
C. Périgaud
GGG. Gosselin
G. Gosselin
SBS. Benzaria
S. Benzaria
JGJ. -L. Girardet
J. -L. Girardet
GMG. Maury
G. Maury
JIJ. -L. Imbach
J. -L. Imbach
It is shown that ddA bis(SATE)phosphotriesters have potent anti-HIV activity in cell culture. Thus, compared with the parent nucleoside, a decrease of 3 or 4 orders of magnitude was observed in the EC50 values for the bis(S-acetyl-2-thioethyl)phosphotriester derivative, which makes this compound as active as AZT.

1 October 2003 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
DED. Egron
D. Egron
JIJ.-L. Imbach
J.-L. Imbach
GGG. Gosselin
G. Gosselin
AAA.-M. Aubertin
A.-M. Aubertin
CPC. Périgaud
C. Périgaud
The synthesis, anti-HIV activity and stability studies of a H-phosphonamidate derivative of 3′-azido-2′,3′-dideoxythymidine (AZT) incorporating a N,N-diisopropylamino residue as first model of alkylamino group are reported. The results demonstrate that such phosphorylated structure exerts its biological effects via chemical hydrolysis into the corresponding H-phosphonate, precursor of the parent nucleoside.